Q2 2026 saw 4% comparable sales growth and a significant margin boost from a US tariff refund, with all segments contributing and strong gains in Personal Health. Guidance for adjusted EBITA margin and free cash flow was raised, while macroeconomic and legal risks remain elevated.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.